Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774454 | 0.80 | LMNA (0.66) | MEN1LMNAKMT2AAR | |
| Hydrochloric Acid SCHEMBL23068261 | 0.78 | LMNA (0.64) | MEN1LMNAKMT2AAR | |
| SCHEMBL30644959 | 0.77 | MAOA (0.45) | MEN1LMNAKMT2A | |
| SCHEMBL20546915 | 0.77 | MAOA (0.45) | MEN1LMNAKMT2A | |
| SCHEMBL13653836 | 0.76 | MEN1 (0.70) | MEN1LMNAKMT2AAR | |
| SCHEMBL6852425 | 0.74 | ALDH1A1 (0.52) | — | |
| SCHEMBL4234485 | 0.73 | AR (0.72) | MEN1LMNAKMT2AARP2RX7 | |
| SCHEMBL13313003 | 0.73 | LMNA (0.66) | MEN1LMNAKMT2AARP2RX7 | |
| SCHEMBL15653783 | 0.72 | AKT2 (0.57) | KMT2A | |
| SCHEMBL20546828 | 0.72 | MAOA (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | MEN1 2774/4885LMNA 4258/4885KMT2A 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.